The WoVen Podcast
Canaan on Twitter
Canaan on LinkedIn
© Copyright 2022 Canaan |
Latest for IDEAYA Biosciences
A milestone in targeted oncology and looking ahead
In honor of this historic event, we want to share a few thoughts about the future of targeted oncology and where we are making investments at Canaan.
BioCentury: With Ideaya deal, GSK bulks up synthetic lethality side of oncology business
A deal with Ideaya gives GSK a path to growing its synthetic lethality pipeline, a corner of the pharma’s cancer rebuild still primarily centered...
IDEAYA & the Next Frontier in Synthetic Lethality
WSJ: Ideaya Biosciences Collects $94 Million for Cancer Therapy
Fierce Biotech: Ideaya, Spelman College team up to provide young African American women a stepping stone to biotech careers
Endpoints News: Billions on the table, GSK’s Hal Barron antes $120M cash to partner with Ideaya
Fierce Biotech: GlaxoSmithKline pens $120M upfront synthetic lethality cancer pact with Fierce 15 winner Ideaya
MedCity News: GSK pumps $120M into partnership with Ideaya in oncology precision medicine play
FierceBiotech: GV, Roche help Ideaya to $94M crossover round, setting stage for synthetic lethality, I-O trials